You Searched For "Rossari Biotech first quarter results" and got 20 results
Sort By:
2 mins read
Inside Rossari Biotech earnings: Input cost falls twice as much as revenue
Rossari recorded 14.3% fall in revenue to ₹109.4 crore but its net profit grew 7.4% to ₹15.2 cro…
3 mins read
Top stocks to watch— Future Retail, IndiGo, SpiceJet, Tata Motors, IndusInd Bank, Coal India, Engineers India, Rossari Biotech, Vodafone-Idea and more
Indian stock market is likely to open on a muted amidst mixed cues from global peers. At 8:00 am th…
3 mins read
Top stocks to watch in trade— ICICI Bank, Oberoi Realty, Godrej Properties, HAL, Infosys, M&M, ITC, Rossari Biotech, Allcargo and more
Amid mixed cues from the global peers, Indian stock-market indices are likely to open on a muted no…
3 mins read
Top stocks to watch today— Wipro, Future Retail, RIL, Divi’s Lab, SBI Life Insurance, Hindalco, Rossari Biotech and more
Indian stock-market indices are likely to open in green on Friday, on the back of positive cues fro…
4 mins read
A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes.
The results from Guardant Health's trial show that blood-based cancer screenings could work, but no…
Leah Rosenbaum
3 mins read
Bharat Biotech to make antigen for first-ever anti-malaria vaccine
The first dose of the vaccine has reached more than 500,000 children since the pilots we…
3 mins read
COVID-19 vaccine latest updates: Sinovac’s CoronaVac safe, early trial results show that vaccine triggers immune response
It takes a decade or two to design, test, and launch an effective vaccine that can protect billi…
3 mins read
Covaxin generated excellent safety data, says Bharat Biotech
Hyderabad, Jan 3 (IANS) Amid the criticism of the Drug Controller General of India (DCGI) for grant…
3 mins read
COVID-19 vaccine latest updates: Spain approves phase III trials of J&J vaccine, Feluda test kit for COVID to be launched in Delhi
The latest wave of COVID-19 infections across the world has taken the global tally of cases over th…
3 mins read
20 million Americans could get a coronavirus vaccine next month, according to the head of Operation Warp Speed
Even more people could start receiving coronavirus shots next year, if the top experimental vaccine…
Andrew Dunn
2 mins read
Moderna, BioNtech surge as COVID-19 vaccine development progresses amid virus spike
BioNtech and Pfizer have already produced millions of doses of its vaccine so it can deliver on pre…
Matthew Fox
3 mins read
Pfizer's CEO repeatedly talked up getting coronavirus vaccine data in October. Now, he's asking for patience.
The pharmaceutical giant has yet to start analyzing data from its final clinical trial, effectively…
Andrew Dunn
2 mins read
Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says
Goldman Sachs raised the vaccine's probability of success to 75% from 70% and projected phase-two s…
Ben Winck
6 mins read
Dispensed: How healthcare is forever changed — a vaccine by fall — reopening the office
Welcome to Dispensed. Inside, the controversy surrounding the rapid COVID-19 test, and what's insid…
Lydia Ramsey
7 mins read
10 surprises that could rock biotech stocks in 2020, from a Regeneron acquisition, to big sales for key drugs on the cusp of launching
One approach that has caught attention is the link between responses to treatments and the microbio…
Lydia Ramsey
1 min read
Rubius Therapeutics surges 84% on encouraging results from early-stage testing of cancer treatment
Rubius stock soared Monday as the company outlined encouraging data from clinical testing of a pote…
Carla Mozée
3 mins read
A biotech founded by a 32-year-old has a shot to launch 'the first new Alzheimer's drug in 15 years'
Donepezil, a cholinesterase inhibitor and the drug that Axovant is pairing with intepirdine in its …
Lydia Ramsey
7 mins read
The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.
The one glaring exception to the string of failures has been Intercept Pharmaceuticals. The small, …
Andrew Dunn
5 mins read
A 'secret' patch shows the future of treating the most common food allergy, and two biotechs are competing to own the $3 billion market
Doctors currently have little to offer patients besides advising them to avoid what they're allergi…
Emma Court
2 mins read
BIOTECHS GET CRUSHED: Here's what you need to know
DON'T MISS: JANET YELLEN: One of these 9 slides makes me think we could get inflation wrong »All th…